Everything on Biotech Diversification

Gilead's $8 billion acquisition of Arcelix is a strategic move to diversify away from antivirals into oncology. This reduces revenue concentration risk and positions Gilead for long-term growth in high-value therapeutic areas.

Impact: Enhances Gilead's pipeline in blood cancer treatments, potentially driving future revenue growth and reducing dependency on legacy drugs.

— from Market Volatility, M&A Deals, and Emerging Market Shifts · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Feb 24, 2026